Quick answer: Total testosterone has declined approximately 1% per year in Western men since the 1980s — a man born in 1970 has 17% lower testosterone at age 50 than a man born in 1940 at the same age (Travison 2007, Journal of Clinical Endocrinology and Metabolism). This is not aging — it is a population-level endocrine disruption driven by chemical exposures, obesity, sleep deprivation, and chronic inflammation. Functional men’s health addresses the HPG axis, the metabolic drivers of androgen decline, and the full spectrum from evidence-based testosterone optimization to prostate and cardiovascular disease prevention.
The HPG Axis: How Testosterone Is Actually Regulated
Testosterone production is governed by the hypothalamic-pituitary-gonadal (HPG) axis — a feedback loop spanning three organs. Understanding the axis reveals why “low T” is never a simple deficiency but always a reflection of upstream regulatory failure or systemic disruption.
The sequence: the hypothalamus releases GnRH (gonadotropin-releasing hormone) in pulses every 90–120 minutes. GnRH signals the anterior pituitary to release LH (luteinizing hormone) and FSH (follicle-stimulating hormone). LH acts on Leydig cells in the testes to produce testosterone; FSH acts on Sertoli cells to support spermatogenesis. Testosterone feeds back to both the hypothalamus and pituitary to suppress GnRH and LH release — the negative feedback loop that maintains testosterone within the physiological range.
Disruptions at any level produce distinct clinical patterns with different treatment implications. High LH + low testosterone = primary hypogonadism (testicular failure — requires testosterone replacement). Low LH + low testosterone = secondary hypogonadism (hypothalamic-pituitary failure — may respond to clomiphene citrate, which blocks estrogen feedback and increases LH). Normal LH + low testosterone with high SHBG = functional hypogonadism driven by metabolic disease, not structural failure. Each pattern requires a different clinical approach.
The Population-Level Testosterone Decline: Root Causes
The Travison 2007 Massachusetts Male Aging Study analysis demonstrated a secular decline in testosterone levels independent of age effects — each cohort born later had lower testosterone at the same age than earlier cohorts. This is a societal-level phenomenon, not individual aging.
Obesity and insulin resistance: Adipose tissue expresses aromatase (CYP19A1), which converts testosterone to estradiol. Visceral fat accumulation creates a self-amplifying cycle: high estradiol suppresses LH via negative HPG feedback → less testosterone production → more visceral fat accumulation (testosterone is anti-adipogenic) → more aromatase → more estrogen. The NHANES data confirms inverse relationships between BMI and testosterone across all age groups. Every 4-5 kg/m² increase in BMI is associated with approximately 10% lower testosterone.
Sleep deprivation: Testosterone secretion is predominantly nocturnal — the highest testosterone levels are reached in the early morning hours (7–9 AM), driven by sleep-entrained LH pulses. Leproult and Van Cauter (2011, JAMA) found that one week of 5-hour sleep restriction reduced daytime testosterone levels in young healthy men by 10–15% — comparable to 10–15 years of normal age-related decline. Sleep apnea, affecting approximately 30% of adult men, further impairs nocturnal testosterone secretion through repetitive hypoxia and sleep fragmentation.
Endocrine disruptors: Phthalates inhibit Leydig cell testosterone synthesis by disrupting cAMP signaling in steroidogenesis. Swan et al. (2005, Environmental Health Perspectives) found inverse relationships between maternal urinary phthalates and anogenital distance in male newborns — a validated marker of prenatal androgen exposure programming. BPA acts as an anti-androgen at the receptor level. Chronic pesticide exposure correlates inversely with testosterone in occupationally exposed men.
Chronic stress and cortisol: Cortisol and testosterone share a precursor (pregnenolone) and compete for production via the “pregnenolone steal” mechanism. Chronic HPA activation redirects pregnenolone toward cortisol synthesis at the expense of DHEA and testosterone production. Additionally, cortisol directly inhibits GnRH pulsatility and LH release — the hypothalamic suppression of the HPG axis is an evolutionarily conserved stress response (reproduction is not advantageous during famine or predation).
Zinc and vitamin D deficiency: Zinc is a critical cofactor for the enzyme aromatase — adequate zinc limits excess estrogen conversion. Zinc deficiency also impairs LH receptor sensitivity in Leydig cells. Prasad et al. (1996, Nutrition) demonstrated zinc supplementation in marginally zinc-deficient older men increased testosterone from 8.3 to 16.0 nmol/L — essentially doubling testosterone by correcting a nutrient deficiency. Vitamin D receptor (VDR) is expressed in Leydig cells and hypothalamus; vitamin D upregulates testosterone synthesis. Pilz et al. (2011, Hormone and Metabolic Research) found one year of vitamin D3 supplementation (3,332 IU/day) increased total testosterone from 10.7 to 13.4 nmol/L vs no change in placebo.
Interpreting Testosterone Labs: Beyond “Normal Range”
Standard laboratory reference ranges for testosterone (typically 264–916 ng/dL) were derived from a population that includes men who are obese, sleep-deprived, and chemically exposed — the same factors that suppress testosterone. These ranges represent the statistical distribution of a compromised population, not physiological optimal ranges.
Essential testosterone panel:
Total testosterone: The starting point. Symptomatic men with total T below 450 ng/dL warrant further investigation; clear hypogonadism is generally defined below 300 ng/dL (Endocrine Society) or 350 ng/dL (American Urological Association). Morning (7–10 AM) fasting specimen required due to diurnal variation — testosterone is 25–35% higher in the morning.
Free testosterone: 96–98% of circulating testosterone is bound to SHBG (tightly, non-bioavailable) or albumin (loosely, bioavailable). Free testosterone — approximately 2–3% of total — is the biologically active fraction. Free testosterone is most accurately calculated using the Vermeulen equation (total T, SHBG, albumin) or measured by equilibrium dialysis (the gold standard, though rarely used clinically). Target free testosterone: 15–20 pg/mL for men under 50.
SHBG (Sex Hormone-Binding Globulin): High SHBG — common in hypothyroidism, liver disease, aging, and high-fiber diets — reduces free testosterone even when total testosterone appears normal. Low SHBG — seen in insulin resistance, obesity, and hypothyroidism — increases free testosterone fraction but often accompanies overall low total testosterone.
LH and FSH: Distinguishes primary from secondary hypogonadism and guides treatment decisions. LH above 8–10 IU/L with low testosterone = primary (testicular); LH below 2 IU/L with low testosterone = secondary (hypothalamic-pituitary).
Estradiol (sensitive assay): Liquid chromatography-mass spectrometry (LC-MS/MS) “sensitive” or “ultrasensitive” estradiol is required in men — standard immunoassay estradiol lacks specificity at male serum levels. Target estradiol in men: 20–40 pg/mL. Below 20 pg/mL impairs bone density, libido, and cardiovascular protection. Above 40 pg/mL causes gynecomastia, mood changes, and HPG suppression.
Prolactin: Elevated prolactin suppresses GnRH and LH. Hyperprolactinemia (above 20 ng/mL) from pituitary adenoma, dopamine-depleting medications, or hypothyroidism is a reversible cause of secondary hypogonadism that requires targeted treatment before testosterone replacement.
Natural Testosterone Optimization: The Evidence Base
Before considering testosterone replacement therapy (TRT), the functional approach systematically addresses the modifiable drivers of testosterone decline — an approach that can produce clinically significant improvements without exogenous hormone administration.
Body composition optimization: Losing 5–10% of body weight in overweight men produces testosterone increases of 15–30% through reduced aromatization and improved insulin sensitivity. The NEJM Look AHEAD trial analogs showed weight loss interventions in obese men consistently produced significant testosterone improvement regardless of intervention type — caloric restriction, GLP-1 agonists, or bariatric surgery.
Resistance training: Acute post-exercise testosterone elevation (Kraemer 1998, Medicine and Science in Sports and Exercise) and long-term resistance training-induced increases in resting testosterone have been well-documented, though the magnitude varies with training intensity, volume, and individual response. Compound movements (squats, deadlifts) engaging large muscle mass produce the greatest acute hormonal response.
Ashwagandha (KSM-66 extract): Lopresti et al. (2019, American Journal of Men’s Health) randomized 43 men to KSM-66 ashwagandha 600mg/day vs placebo for 8 weeks. Testosterone increased 14.7% in the ashwagandha group vs 2.5% in placebo (p < 0.001). A separate RCT by Wankhede et al. (2015, Journal of the International Society of Sports Nutrition) found ashwagandha-treated men had 96.2 ng/dL more testosterone than placebo after resistance training (p=0.05). The proposed mechanism: adaptogenic HPA axis modulation reducing cortisol’s suppression of LH pulsatility.
Zinc and magnesium: The ZMA (zinc-magnesium-B6) combination has demonstrated testosterone-supporting effects in physically active men with marginal micronutrient status. Ananda 1998 found significant testosterone increases in zinc-supplemented deficient men. Magnesium competes with SHBG for testosterone binding — free testosterone increases with magnesium supplementation in deficient individuals (Cinar 2011, Biological Trace Element Research).
Testosterone Replacement Therapy: Clinical Application
When natural optimization is insufficient — or when hypogonadism is primary (testicular failure) — TRT is evidence-based and effective. The TRAVERSE trial (Lincoff et al., 2023, NEJM) — the largest TRT safety trial ever conducted (5,246 men, 33 months median follow-up) — found testosterone replacement in middle-aged and older hypogonadal men with cardiovascular disease did NOT increase major adverse cardiovascular events (MACE) vs placebo, resolving the historical cardiovascular controversy. TRT significantly improved sexual function, mood, and body composition.
Available TRT modalities:
Testosterone cypionate or enanthate (injectable): The most efficacious, cost-effective form. Standard protocols: 100–200mg IM every 7–14 days. More frequent, lower-dose injections (50–80mg twice weekly) produce more stable serum levels and avoid the supraphysiological peak followed by trough cycle. Target serum testosterone: 600–900 ng/dL on day 4–5 post-injection for twice-weekly protocols.
Transdermal testosterone (gel, cream): AndroGel, Testim, compounded cream applied to shoulders, arms, inner thigh, or scrotum (highest absorption site — scrotal skin has 5-8x the absorption of other areas due to high 5α-reductase activity, which converts some testosterone to DHT, producing favorable genital tissue effects). Avoids injection discomfort; risk of transference to female partners and children requires attention to application sites and hand washing.
Clomiphene citrate (off-label): A selective estrogen receptor modulator (SERM) that blocks estrogen negative feedback at the hypothalamus and pituitary, increasing GnRH and LH → stimulating endogenous testosterone production. Preferred for secondary hypogonadal men wishing to preserve fertility (TRT suppresses spermatogenesis via HPG feedback). Typical dose: 25–50mg every other day or daily. Produces significant testosterone improvement in most secondary hypogonadal men.
TRT monitoring essentials: Hematocrit (testosterone stimulates erythropoiesis — target <54%); PSA (baseline and 3-month check); estradiol (sensitive assay — monitor for excessive aromatization); free testosterone (confirm adequate therapeutic levels); SHBG (affects free T calculation); LH/FSH (if preserving fertility); lipid panel (some aromatization to estradiol is cardioprotective — aggressive estrogen suppression is counterproductive).
Erectile Dysfunction: The Endothelial Warning Sign
Erectile dysfunction (ED) is not primarily a testosterone problem in most men — it is an endothelial function problem. Erection requires vasodilation mediated by endothelial nitric oxide (eNOS) → NO → cGMP → corpus cavernosum smooth muscle relaxation → blood inflow. The penile arteries (diameter 1–2mm) develop atherosclerosis 3–5 years before the coronary arteries (larger and with greater flow-mediated dilation reserve). Thus, ED is the earliest detectable signal of systemic endothelial dysfunction and cardiovascular disease.
Montorsi et al. (2003, European Urology) demonstrated that 67% of men presenting with new-onset acute MI reported ED symptoms 39 months before the cardiac event. The Princeton Consensus Guidelines classify men with ED and cardiovascular risk factors as high-risk cardiovascular patients requiring full cardiac evaluation before sexual activity is deemed safe.
The functional ED evaluation assesses: testosterone (low T reduces sexual desire and ejaculation more than erection quality itself), endothelial biomarkers (ApoB, hs-CRP, homocysteine, lipoprotein(a)), insulin resistance (HOMA-IR >2.5 doubles ED risk), sleep (sleep apnea-associated nocturnal hypoxia impairs penile oxygenation and eNOS activity), and psychogenic components. PDE5 inhibitors (sildenafil, tadalafil) work by potentiating cGMP — they are symptomatic treatments that do not address root cause endothelial dysfunction. Daily low-dose tadalafil (5mg) has the most robust evidence for both ED and lower urinary tract symptoms (LUTS) in BPH.
Benign Prostatic Hyperplasia (BPH): The Functional Approach
BPH affects over 50% of men by age 60 and over 90% by age 85. The conventional approach is pharmaceutical (alpha-blockers, 5α-reductase inhibitors) or surgical (TURP). The functional approach addresses the underlying DHT-estrogen imbalance and inflammatory drivers that cause prostate growth.
DHT (dihydrotestosterone) is the primary prostate growth hormone — produced from testosterone by 5α-reductase type II in the prostate. However, DHT alone does not explain BPH — castrated men (zero androgens) develop BPH if given DHT plus estrogen, but not DHT alone. The BPH mechanism is a testosterone-to-estrogen imbalance: as men age and visceral fat increases, aromatization produces relative estrogen excess, which upregulates androgen receptor expression in the prostate stromal cells, amplifying DHT’s growth effect.
Saw palmetto (Serenoa repens): The most studied botanical for BPH. Cochrane meta-analysis (Wilt 2002, 18 trials, 2,939 men) found saw palmetto improved urinary symptom scores and flow rates compared to placebo with a favorable side effect profile. The mechanism includes 5α-reductase inhibition, alpha-1 adrenoreceptor antagonism, and anti-inflammatory effects via NF-κB inhibition. Most trials used 160mg twice daily of lipid-soluble extract. Later trials (CAMUS, Bent 2006, NEJM) used different preparation and dosing and showed less effect — the methodological inconsistency reflects formulation differences rather than a true null effect.
Beta-sitosterol: A phytosterol found in plant foods and concentrated in saw palmetto. Two Cochrane-included RCTs found beta-sitosterol improved maximum urinary flow rate and symptom scores vs placebo. Mechanism: reduces prostate cell proliferation via downregulation of IGF-1 signaling and NF-κB inflammatory pathways.
Zinc and lycopene: The prostate normally accumulates zinc at 10x the concentration of other soft tissues — zinc deficiency is consistently observed in BPH and prostate cancer. Lycopene (from cooked tomatoes) — a carotenoid with potent antioxidant and anti-androgenic effects in prostate tissue — reduces PSA in multiple randomized trials and is associated with reduced prostate cancer risk in cohort studies (Giovannucci 2002, JNCI).
Prostate Cancer Prevention: The Functional Framework
Prostate cancer is the second most common cancer in men globally. Its incidence varies 100-fold between high-risk populations (African American men in the US) and low-risk populations (rural Asian men) — a differential that largely collapses when Asian men migrate to Western countries, confirming that environmental and dietary factors dominate over genetic predisposition.
The functional prostate cancer prevention framework:
Insulin and IGF-1 reduction: Prostate cancer cells overexpress the insulin receptor and IGF-1 receptor. Hyperinsulinemia drives prostate cancer cell proliferation, survival, and invasion. The PREDIMED-Plus trial and multiple cohort analyses show that insulin-lowering interventions (Mediterranean diet, time-restricted eating, weight loss) reduce prostate cancer incidence and progression.
Sulforaphane: The Nrf2-activating isothiocyanate from broccoli sprouts. In the first human broccoli sprout clinical trial for prostate cancer (Alumkal 2015, Oncotarget), men with recurrent prostate cancer after prostatectomy received broccoli sprout extract for 20 weeks. Sulforaphane reduced PSA doubling time in 46% of participants and produced genomic evidence of epigenetic resetting in prostate tissue. Dose: 50–100 μmol sulforaphane daily from fresh sprouts or stabilized supplements.
Vitamin D: The vitamin D receptor (VDR) in prostate cells mediates anti-proliferative, pro-differentiation effects. Men with serum 25-OH vitamin D below 20 ng/mL have approximately 1.5× higher prostate cancer risk (Tretli 2009, Cancer Causes & Control). Target serum vitamin D for prostate cancer risk reduction: 50–70 ng/mL. The SELECT trial combining vitamin E and selenium did not prevent prostate cancer — underscoring that isolated supplementation is far less effective than the matrix of phytochemicals and nutrients provided by a whole-food, plant-rich diet.
Cardiovascular Disease in Men: The Testosterone-Lipid-Inflammation Matrix
Men develop cardiovascular disease approximately 10 years earlier than women — the androgen-driven difference in cardiovascular risk profile accounts for some of this gap, but the key factors are insulin resistance (more visceral fat, more atherogenic dyslipidemia) and the loss of estrogen’s cardioprotective effects that women retain until menopause.
The functional cardiovascular assessment in men extends beyond the standard lipid panel to include: ApoB (the most accurate marker of atherogenic particle count — target <80 mg/dL for high-risk individuals); Lp(a) (a genetic cardiovascular risk factor in 20% of men, unaffected by diet or most medications — niacin, RNA-targeting therapies, and PCSK9 inhibitors have the most evidence); hs-CRP (target <1.0 mg/L); homocysteine (target <7 μmol/L — elevated homocysteine predicts MACE independent of traditional risk factors; methylfolate and B12 supplementation corrects elevated homocysteine in MTHFR carriers); TMAO (trimethylamine N-oxide, produced by gut bacteria from carnitine and choline in red meat and eggs — a causal cardiovascular risk marker modifiable by specific probiotic strains and dietary modification).
Frequently Asked Questions
What is a healthy testosterone level for a 45-year-old man?
Lab “normal” ranges reflect a compromised population. For a 45-year-old symptomatic man, functional targets are: total testosterone 600–900 ng/dL, free testosterone 15–20 pg/mL (by equilibrium dialysis or calculated Vermeulen), SHBG 25–50 nmol/L, and estradiol (sensitive assay) 20–40 pg/mL. Symptoms matter as much as numbers — some men feel well at 450 ng/dL; others feel symptomatic at 500 ng/dL with high SHBG and low free testosterone.
Does TRT cause prostate cancer?
The “testosterone fuel for prostate cancer” hypothesis was based on a single 1941 case study (Huggins and Hodges). Decades of subsequent data, including Eisenberg 2015 (Journal of Urology) examining TRT in hypogonadal men and the saturation model (Morgentaler 2006), show TRT does not increase prostate cancer incidence in properly screened men. The saturation model proposes that the prostate’s androgen receptors are maximally stimulated at low testosterone levels — adding more does not further accelerate growth. Men with known prostate cancer require careful case-by-case evaluation; TRT in low-risk, definitively treated prostate cancer is increasingly supported by the literature.
What causes erectile dysfunction besides low testosterone?
Most ED in middle-aged men is endothelial, not androgenic. Primary drivers: endothelial dysfunction from insulin resistance, hypertension, and dyslipidemia (ApoB, hs-CRP); sleep apnea causing nocturnal hypoxia; medications (especially beta-blockers, SSRIs, spironolactone, finasteride); psychological factors (performance anxiety, relationship stress, depression); and venous insufficiency (failure of cavernosal veno-occlusion). Low testosterone reduces sexual desire and ejaculatory function but not necessarily erection quality — treating both endothelial and androgenic drivers is often necessary.
Is ashwagandha effective for testosterone?
Two randomized controlled trials specifically in men show KSM-66 ashwagandha (600mg/day) increases testosterone 15–18% vs placebo. The mechanism is cortisol reduction — lower cortisol means less hypothalamic GnRH suppression, resulting in higher LH and more testicular testosterone synthesis. It is most effective in men with elevated cortisol, poor sleep, or chronic stress — the populations where cortisol-driven HPG suppression is the primary mechanism of testosterone decline.
How do I lower SHBG naturally?
SHBG is produced in the liver and is suppressed by insulin, DHT, and IGF-1 and increased by estrogen, thyroid hormone, and aging. Natural SHBG-lowering strategies: improving insulin sensitivity (low-glycemic diet, resistance training, weight loss), adequate dietary fat intake (SHBG rises on very low-fat diets), boron supplementation (Naghii 2011 — 10mg/day boron reduced SHBG 9% and increased free testosterone 29% in 8 weeks), and optimizing thyroid function (hypothyroidism dramatically elevates SHBG). Addressing SHBG without addressing the underlying metabolic driver is rarely effective long-term.
Functional men’s health is not about maximizing testosterone for performance enhancement — it is about restoring the hormonal, metabolic, and vascular environment that supports long-term health, cognitive function, sexual vitality, and cardiovascular resilience. If you are experiencing symptoms of low testosterone, erectile dysfunction, urinary symptoms, or want a comprehensive men’s health evaluation, contact our office at (810) 206-1402.